In patients with preclinical AD, plasma GFAP levels were found to be higher in cognitively unimpaired older adults with the presence of brain amyloidosis compared with those without [27, 38], suggesting that plasma GFAP is an early biomarker for Aβ pathology. The gene discussed is GFAP; the disease is Alzheimer disease.